Pasireotide

About the Target

Pasireotide (SOM230) is a multi-receptor ligand somatostatin analogue with high binding affinity for somatostatin receptor (SSTR) subtypes sst1,2,3 and sst5. The mapped target for this entry is Somatostatin receptors 1, 2, 3 and 5 (SSTR1, SSTR2, SSTR3, and SSTR5). This target context is most often investigated as part of ligand-responsive signaling, where receptor occupancy can reshape downstream second-messenger output, trafficking, secretion, excitability, or transcriptional programs. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. This framing is especially useful when investigators want to connect a controlled ligand stimulus with rapidly changing cellular phenotypes.

Research Context

As an agonist-format peptide, it is typically used to trigger pathway activation on demand and to compare acute signaling events with longer adaptive changes such as receptor desensitization or altered transcriptional output. In practice, dose-response design, timing, and matched control conditions are important for separating direct target engagement from delayed compensatory responses. Because more than one mapped molecular node is represented in the enrichment, pathway readouts should be interpreted with awareness that the phenotype may integrate multiple signaling inputs.

• pair peptide treatment with pathway-proximal signaling or trafficking readouts whenever possible
• compare responses across cell states or model systems with different receptor abundance
• distinguish primary target engagement from downstream adaptation during longer incubations

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

The standard product format is most useful for reproducible baseline experiments, matched comparative studies, and workflows that need a consistent reagent across assay repeats. In comparative workflows, consistency of preparation, exposure window, and matched controls is often as important as the nominal treatment itself. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.